Tumor mutational burden
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer
... Fig. 2 tTMB fold-change based on multi-regions compared with single region. a For overall patients. For overall analysis, tTMB fold-change is computed by the mean tTMB of two-regions, three-regions, four-regions, ...
5
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
... highest mutational loads across cancer types, likely owing to tobacco-induced mutagen- esis, which is characterized by a high transversion/transi- tion ratio and increased genomic instability ...quantify ...
9
Designing gene panels for tumor mutational burden estimation: the need to shift from ‘correlation’ to ‘accuracy’
... Additional file 1: Figure S1. The tumor mutational burden across 33 cancer types in TCGA. Figure S2. The correlation between F1CDx- and WES-based TMB in PAAD after the removal of a relatively ...
7
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
... Circulating tumor DNA; DLBC: Lymphoid neoplasm diffuse large B-cell lymphoma; ESCA: Esophageal carcinoma; FDA: Food and Drug Administration; GBM: Glioblastoma; GEP: Gene expression profile; HLA: Human Leukocyte ...
13
<p>Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China</p>
... Tumor mutational burden (TMB) has demonstrated itself as a new estimated biomarker in NSCLC. 13,14 Previous study demonstrated that patients with TMB- high had prolonged PFS after they received ...
8
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
... the tumor mutational burden (TMB), defined as the total number of mutations per coding area of a tumor ...Each tumor mutation within a cancer cell has the potential to give rise to ...
11
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma
... 5255 tumor/normal samples representing 12 tumor types from TCGA and found a positive correlation between somatic CNVs level and the total number of mutations [38], suggesting the potential value of CNVs for ...
13
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
... Immunotherapy CPI combinations have proven effective in melanoma, and CheckMate-214 was the first in mRCC to use combination of CTLA-4 and PD-1 inhibitors. CHECKMATE 214 was a phase III trial which randomized 1040 ...
10
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
... both tumor tissue samples and peripheral blood lymphocytes for each patient were proc- essed for pairwise variant calling using VarScan ...in tumor tissue samples; the P value threshold to call a somatic ...
14
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
... To confirm that PMS2 promoter mutations were som- atic in origin, we carried out several analyses. We first looked in TCGA whole exome data from 50 melanoma patients and confirmed the somatic status of three of the ...
14
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
... of mutational burden estimation and re- sponse to ...some tumor types, such as lung can- cer, these driver mutations do not contribute to “ non- self” immunogenicity in a manner comparable to nonsy- ...
12
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
... by tumor cells as well as detection of intratumoral microsatel- lite instability (MSI-H) were approved as inclusion criteria for anti-PD1 treatment of cancer ...nonsynonymous tumor mutational ...
8
Extraskeletal myxoid chondrosarcoma with massive pulmonary metastases
... tumor size was 14.8 cm in greatest dimension, the clos- est margin was less than 0.5 mm from the tumor. Next generation sequencing (NGS) was performed using a commercially available platform; it showed the ...
6
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
... of tumor mutational burden and PD-L1 status in predicting response to treatment, providing additional impetus for de- veloping tissue-agnostic therapies [39, ...
7
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor
... It is clear that in cancers with a high number of mutations, tumor mutational burden correlates with immunotherapy response (33). However, the role of neoepitopes in the immune response of cancers ...
16
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
... against tumor cells, have shown immense promise in the treatment of various ...Currently, tumor mutational burden (TMB) and programmed death ligand 1 (PD-L1) expression are the primary ...
18
The degree of intratumor mutational heterogeneity varies by primary tumor sub-site
... Various differences between the larynx, FOM and the oral tongue may account for the disparity of incidence in mutations at these sites. The anterior two- thirds [20] of the tongue and the floor-of-mouth arise from ...
14
PARP inhibitors: Synthetic lethality in the clinic.
... DNA mutational scar assessed by calculating the extent of chromosomal loss of heterozygosity (LOH) across the genome: (i) BRCA mutant (gBRCAm or sBRCAm); (ii) BRCA wild-type but with high genomic LOH; and (iii) ...
23
Bioluminescence imaging and two-photon microscopy guided laser ablation of GBM decreases tumor burden
... Laser ablation can be used in minimally invasive surgery for diseased tissue. Intraoperative laser ablation has been proposed for neurosurgical resection, and the results of laser ablation have been evaluated and ...
14
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
... TP53-mutational burden in lower- risk MDS patients is not currently well ...TP53 mutational load on MDS survival, we determined the optimal cut-off of VAF for identifying differences in ...greater ...
14